Method of reducing pre-and post-ischemic myocardial arrhythmias and fibrillation

• US 4,962,095 A
• Filed: 12/18/1989
• Issued: 10/09/1990
• Est. Priority Date: 02/15/1989
• Status: Expired due to Term

• Current Assignee: E R Squibb & Sons Incorporated
• Original Assignee: E R Squibb & Sons Incorporated
• Inventors: Bergey, James L., Grover, Gary J.
• Primary Examiner(s): Gerstl, Robert
• Application Number:
  US07/451,667
• Time in Patent Office: 295 Days
• Field of Search: 514/91
• US Class Current: 514/91
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 38/166 Streptokinase
• CPC Class Codes: A61K 38/49 Urokinase; Tissue plasminogen activator

Abstract

Zofenopril, fosinopril, (S)-1-[6-amino-2-[[hydroxy (4-phenylbutyl) phosphinyl]oxy]-1-oxohexyl]-L-proline or a pharmaceutically acceptable salt thereof alone or in combination with a thrombolytic, antiarrhythmic, or antifibrillatory agent is employed to reduce pre-and post- ischemic myocardial arrhythmias and fibrillations as well as reducing arrhythmias associated with congestive heart failure.

Claims

1. A method of reducing pre- and post-ischemic arrhythmias and fibrillation as well as reducing arrhythmias associated with congestive heart failure in a mammalian species which comprises administering to a mammalian species in need of such treatment an effective amount of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline or a pharmaceutically acceptable salt thereof alone or in combination with a thrombolytic agent, antiarrhythmic agent, or antifibrillatory agent or with a non-pharmaceutical reperfusion technique.

2. The method of claim 1 wherein the only therapeutic agent employed is (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 wherein the agents employed are (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline or a pharmaceutically acceptable salt thereof and a thrombolytic agent, an antiarrhythmia agent, or an antifibrillatory agent.

4. The method of claim 3 wherein the other agent is a thrombolytic agent selected from the group consisting of tissue plasminogen activator (tPA), recombinant tissue plasminogen activator, streptokinase, urokinase, and prourokinase.

5. The method of claim 3 wherein the other agent is an antiarrhythmic or antifibrillatory agent selected from the group consisting of quinidine, procainamide, disopyramide, lidocaine, tocainide, phenyltoin, flecainide, encainide, amiodarone, bretylium, clofilium, verapamil, diltiazem, propanolol, sotalol, nadolol, and metoprolol.